These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36682363)

  • 1. Lenalidomide following whole-brain radiotherapy in patients with primary central nervous system lymphoma ineligible for intensive systemic therapy.
    Bagal B; Sarma R; Dey S; Nayak L; Bonda A; Goda J; Khanna N; Dasgupta A; Kakoti S; Chatarjee A; Jain H; Epari S; Laskar S; Sengar M; Gupta T
    Br J Haematol; 2023 Apr; 201(1):150-153. PubMed ID: 36682363
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary CNS lymphoma: chemotherapy followed by radiotherapy or chemotherapy alone? A randomized multicentric study.
    Thiel E; Korfel A; Hinkelbein W
    Front Radiat Ther Oncol; 1999; 33():349-53. PubMed ID: 10549506
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.
    Vu K; Mannis G; Hwang J; Geng H; Rubenstein JL
    Br J Haematol; 2019 Jul; 186(1):180-183. PubMed ID: 30714128
    [No Abstract]   [Full Text] [Related]  

  • 5. Primary central nervous system lymphoma: curable without toxicity?
    DeAngelis LM
    Cancer J Sci Am; 1996; 2(3):137-9. PubMed ID: 9166513
    [No Abstract]   [Full Text] [Related]  

  • 6. [Lenalidomide, rituximab and dexamethasone for the treatment of recurrent/refractory or elderly newly diagnosed patients with primary central nervous system lymphoma: 5 cases report and literature review].
    Bai JF; Feng R; Han HX; Wang T; Li JT; Zhang CL; Liu H
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1047-1049. PubMed ID: 32023740
    [No Abstract]   [Full Text] [Related]  

  • 7. Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.
    Yuan X; Xie Y; Xu N; Liu H; Chen P; Zhao A; Liang Y; Qian W
    Haematologica; 2024 Jun; 109(6):2005-2009. PubMed ID: 38356447
    [No Abstract]   [Full Text] [Related]  

  • 8. Primary CNS lymphoma.
    Gerstner E; Batchelor T
    Expert Rev Anticancer Ther; 2007 May; 7(5):689-700. PubMed ID: 17492932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
    J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Journal Club: Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.
    Alnahhas I; Malkin M
    Neurology; 2015 Dec; 85(24):e187-9. PubMed ID: 26668244
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of primary central nervous system lymphoma: still more questions than answers.
    Fine HA
    Blood; 1995 Oct; 86(8):2873-5. PubMed ID: 7579377
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances for the treatment of primary central nervous system lymphoma (review).
    Yamanaka R; Tanaka R
    Oncol Rep; 2004 Sep; 12(3):563-8. PubMed ID: 15289838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
    Korfel A; Thiel E
    Leuk Lymphoma; 1998 Aug; 30(5-6):609-17. PubMed ID: 9711923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
    Alvarnas JC; Negrin RS; Horning SJ; Hu WW; Long GD; Schriber JR; Stockerl-Goldstein K; Tierney K; Wong R; Blume KG; Chao NJ
    Biol Blood Marrow Transplant; 2000; 6(3A):352-8. PubMed ID: 10905773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
    Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
    J Neurooncol; 2021 Sep; 154(2):207-217. PubMed ID: 34331673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy is effective as early treatment for primary central nervous system lymphoma.
    Boiardi A; Silvani A; Pozzi A; Fariselli L; Broggi G; Salmaggi A
    J Neurol; 1999 Jan; 246(1):31-7. PubMed ID: 9987711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma-a single-center retrospective study.
    Guo XL; Zhao ZY; Guo XF; Zuo YB; Li JA; Nie ZY; Ren JH
    Neurol Sci; 2024 Jun; 45(6):2931-2934. PubMed ID: 38326666
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy.
    DeAngelis LM
    J Neurooncol; 1999 Jul; 43(3):249-57. PubMed ID: 10563431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
    Laack NN; O'Neill BP; Ballman KV; O'Fallon JR; Carrero XW; Kurtin PJ; Scheithauer BW; Brown PD; Habermann TM; Colgan JP; Gilbert MR; Hawkins RB; Morton RF; Windschitl HE; Fitch TR; Pajon ER;
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):476-82. PubMed ID: 20800387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
    Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
    Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.